Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole QW in Acute Schizophrenia
NCT05325645Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in schizophrenia (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Positive and Negative Syndrome Scale total score at 7 weeks. Started Jul 2022; status: recruiting.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05325645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325645.